Patents Issued in October 18, 2016
-
Patent number: 9468598Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.Type: GrantFiled: April 30, 2013Date of Patent: October 18, 2016Assignee: AstraZeneca ABInventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
-
Patent number: 9468599Abstract: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation.Type: GrantFiled: April 16, 2012Date of Patent: October 18, 2016Assignee: CMPD LICENSING, LLCInventors: Jay Richard Ray, II, Charles D. Hodge
-
Patent number: 9468600Abstract: The present invention is directed to compositions and processes for their use that allow for the delivery of physiologically active agents, using a unique composition containing glycerin and triglycerides in the proper ratio. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water and physiologically active agents in place. The presence of both hydrophobic and hydrophilic components of the current invention solubilize the physiologically actives into the complex matrix, keeping the actives on the skin and allowing them to penetrate the skin over time, thus delivering the actives to the blood stream.Type: GrantFiled: March 23, 2015Date of Patent: October 18, 2016Assignee: DR. HOLMQUIST HEALTHCARE, LLCInventors: C. Scott Danos, Bruce A. Cranner, Anne-Marie T. Karp
-
Patent number: 9468601Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.Type: GrantFiled: July 13, 2015Date of Patent: October 18, 2016Assignee: CMPD LICENSING, LLCInventor: Jay Richard Ray, II
-
Patent number: 9468602Abstract: The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.Type: GrantFiled: January 5, 2010Date of Patent: October 18, 2016Assignee: AZAD Pharma AGInventors: Fabio Carli, Elisabetta Chiellini, Van Van Khov-Tran, Mihran Baronian
-
Patent number: 9468603Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.Type: GrantFiled: September 13, 2014Date of Patent: October 18, 2016Assignee: ARBOR THERAPEUTICS, LLCInventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
-
Patent number: 9468604Abstract: In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.Type: GrantFiled: April 1, 2014Date of Patent: October 18, 2016Assignee: Bend Research, Inc.Inventors: Dwayne T. Friesen, Michael J. Gumkowski, Rodney James Ketner, Douglas A. Lorenz, James A. S. Nightingale, Ravi M. Shanker, James B. West
-
Patent number: 9468605Abstract: Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-? production in mammals.Type: GrantFiled: June 16, 2014Date of Patent: October 18, 2016Assignee: Celgene CorporationInventors: Darshan K. Parikh, Anil Menon, Anthony Tutino
-
Patent number: 9468606Abstract: A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, an active ingredient, and C) from about 0.1% to about 20% by weight of at least one solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.Type: GrantFiled: March 31, 2014Date of Patent: October 18, 2016Assignee: Johnson & Johnson Consumer Inc.Inventors: Ying Sun, Jeffrey M. Wu, Ali Fassih
-
Patent number: 9468607Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.Type: GrantFiled: October 9, 2008Date of Patent: October 18, 2016Assignee: WASHINGTON UNIVERSITYInventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
-
Patent number: 9468608Abstract: The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.Type: GrantFiled: October 24, 2014Date of Patent: October 18, 2016Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: Wuu-Jyh Lin, Ting-Shien Duh, Wei-Ming Li, Ming-Hsin Li
-
Patent number: 9468609Abstract: This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.Type: GrantFiled: March 13, 2014Date of Patent: October 18, 2016Assignee: LYCORED LTD.Inventors: Rachel Levy, Nurit Hadad, Tanya Sedlov, Morris Zelkha
-
Patent number: 9468610Abstract: The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.Type: GrantFiled: September 10, 2008Date of Patent: October 18, 2016Assignee: MERZ PHARMA GmbH & CO. KGaAInventor: Hagen Kruger
-
Patent number: 9468611Abstract: The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.Type: GrantFiled: March 14, 2013Date of Patent: October 18, 2016Assignee: Relmada Therapeutics, Inc.Inventors: Paolo L. Manfredi, Charles E. Inturrisi
-
Patent number: 9468612Abstract: Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.Type: GrantFiled: October 26, 2011Date of Patent: October 18, 2016Assignee: Seattle Children's HospitalInventors: Allison A. Eddy, Daryl M. Okamura
-
Patent number: 9468613Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.Type: GrantFiled: May 20, 2015Date of Patent: October 18, 2016Assignee: Tosk, Inc.Inventors: William A. Garland, Brian D. Frenzel
-
Patent number: 9468614Abstract: A method of moisturizing while decolonizing mammalian tissue, comprising applying a multi-valent cationic antiseptic composition to the tissue, and applying a moisturizer composition to at least a portion of the same tissue is provided. An oral care kit comprising a composition comprising the multi-valent cationic antiseptic and the moisturizer composition, and a method of moisturizing oral tissue of a patient requiring intubation using the moisturizer composition and an endotracheal tube coated or impregnated with a cationic antiseptic are also provided.Type: GrantFiled: May 14, 2013Date of Patent: October 18, 2016Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Katie F. Wlaschin, Alan R. Dombrowski, Matthew T. Scholz, Ranjani V. Parthasarathy
-
Patent number: 9468615Abstract: Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes.Type: GrantFiled: July 10, 2014Date of Patent: October 18, 2016Assignee: Algiax Pharmaceuticals GmbHInventors: Birgit Hasse, Guido Koopmans
-
Patent number: 9468616Abstract: Provided herein are a composition for preventing or treating inflammatory diseases or infectious diseases which contains m-3M3FBS or a pharmaceutically available salt thereof as an active ingredient, and health supplements for improving or preventing inflammatory diseases or infectious diseases which contain m-3M3FBS. Since m-3M3FBS has a microbicidal effect, inhibition of apoptosis, and inhibition of LPS-involved signal transduction which enables to effectively treat or prevent inflammatory diseases or infectious diseases, so that it may be effectively used as medicine or health supplements for treating or preventing inflammatory diseases or infectious diseases.Type: GrantFiled: March 14, 2012Date of Patent: October 18, 2016Assignee: Research & Business Foundation SUNGKYUNKWAN UNIVERSITYInventors: Yoe Sik Bae, Sang Doo Kim
-
Patent number: 9468617Abstract: Topical pharmaceutical gel compositions of diclofenac sodium are provided. The topical gel compositions contain at least about 10% w/w diclofenac sodium and are suitable for once-a-day topical application.Type: GrantFiled: December 12, 2014Date of Patent: October 18, 2016Assignee: LUPIN ATLANTIS HOLDINGS SAInventor: Bala Chandran Nayar
-
Patent number: 9468618Abstract: A topical pharmaceutical gel composition of diclofenac sodium suitable for once-a-day topical application is provided. The topical gel composition contains at least about 10 % w/w of diclofenac sodium and once-a-day application of the composition provides relief from pain or inflammation comparable to that achieved with four times daily application of diclofenac sodium 1 % or 3 % topical gel.Type: GrantFiled: December 13, 2014Date of Patent: October 18, 2016Assignee: LUPIN ATLANTIS HOLDINGS SAInventor: Bala Chandran Nayar
-
Patent number: 9468619Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: GrantFiled: June 13, 2013Date of Patent: October 18, 2016Assignee: Bracco S.P.A.Inventors: Aldo Pinchera, Livio Cavalieri, Federico Maisano, Giovanni Rivolta, Ferruccio Santini, Fulvia Vella
-
Patent number: 9468620Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.Type: GrantFiled: February 26, 2014Date of Patent: October 18, 2016Assignee: Andida Pharma, Inc.Inventor: Per Gjorstrup
-
Patent number: 9468621Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.Type: GrantFiled: September 19, 2012Date of Patent: October 18, 2016Assignees: IHI CorporationInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Patent number: 9468622Abstract: The present invention provides ?-keto peracids and methods for producing and using the same. In particular, ?-keto peracids are useful as antimicrobial agents.Type: GrantFiled: March 27, 2015Date of Patent: October 18, 2016Assignee: CHD Bioscience, Inc.Inventors: Edwin D. Neas, John D. Skinner
-
Patent number: 9468623Abstract: The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.Type: GrantFiled: April 15, 2016Date of Patent: October 18, 2016Assignee: Hong Kong Baptist UniversityInventors: Hong-xi Xu, Yuan-zhi Lao, Zhi-jie Ding, Hong Zhang, Kai-xian Chen, Hong-sheng Tan, Zhao-xiang Bian, Cheng-yuan Lin, Shi-lin Chen, Da-jian Yang, Ai-ping Lu, Albert Sun Chi Chan
-
Patent number: 9468624Abstract: A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum. The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.Type: GrantFiled: June 15, 2015Date of Patent: October 18, 2016Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Bonnie L. Bassler, Lee R. Swem, Scott M. Ulrich, Colleen T. O'Loughlin
-
Patent number: 9468625Abstract: The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof.Type: GrantFiled: September 10, 2015Date of Patent: October 18, 2016Assignee: EpicentRx, Inc.Inventors: Jan Scicinski, Bryan T. Oronsky
-
Patent number: 9468626Abstract: Pharmaceutical formulations comprising nanoparticles of melatonin are useful for the treatment of neonatal brain injury.Type: GrantFiled: March 10, 2015Date of Patent: October 18, 2016Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Annamaria Soliani Raschini, Akif Emre Türeli, Eva Marie Prinz
-
Patent number: 9468627Abstract: The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor.Type: GrantFiled: April 19, 2013Date of Patent: October 18, 2016Assignee: Duke UniversityInventors: Jacob P. R. Jacobsen, Marc G. Caron
-
Patent number: 9468628Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.Type: GrantFiled: March 3, 2016Date of Patent: October 18, 2016Assignee: PHARMAKEA, INCInventors: John Howard Hutchinson, David Lonergan
-
Patent number: 9468629Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.Type: GrantFiled: December 17, 2015Date of Patent: October 18, 2016Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
-
Patent number: 9468630Abstract: Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.Type: GrantFiled: August 13, 2013Date of Patent: October 18, 2016Assignee: Knopp Biosciences LLCInventors: Michael E. Bozik, Gregory Hebrank, Wildon Farwell, Thomas Petzinger, Jr., Steven Dworetzky
-
Patent number: 9468631Abstract: The subject invention describes a method of use of Ropinirole™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidine™ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.Type: GrantFiled: April 4, 2014Date of Patent: October 18, 2016Inventor: Robert L. Knobler
-
Patent number: 9468632Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against cancer stem cells.Type: GrantFiled: November 26, 2013Date of Patent: October 18, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Ronald Buckanovich, Scott D. Larsen, Kun Yang
-
Patent number: 9468633Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.Type: GrantFiled: August 20, 2012Date of Patent: October 18, 2016Assignee: Andrx Pharmaceuticals, Inc.Inventors: Manesh Dixit, Chih-Ming Chen, Xiu Xiu Cheng, Jianbo Xie
-
Patent number: 9468634Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: GrantFiled: March 15, 2013Date of Patent: October 18, 2016Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Patent number: 9468635Abstract: The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.Type: GrantFiled: January 7, 2015Date of Patent: October 18, 2016Assignee: KBP BIOSCIENCES CO., Ltd.Inventors: Zhenhua Huang, Jinyuan Wang, Dedong Zhang
-
Patent number: 9468636Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.Type: GrantFiled: February 20, 2015Date of Patent: October 18, 2016Assignee: MALLINCKRODT LLCInventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
-
Patent number: 9468637Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.Type: GrantFiled: May 13, 2010Date of Patent: October 18, 2016Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
-
Patent number: 9468638Abstract: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic surfactant/emulsifier in a concentration of from about 20% to about 50%, a co-surfactant in a concentration from about 10% to about 45% and a stabilizer in a concentration of from about 1% to about 15%.Type: GrantFiled: September 22, 2011Date of Patent: October 18, 2016Assignee: Texas Southern UniversityInventors: Dong Liang, Lei Wu, Mathew Kizhakkekara Joseph, Jyothy Anie John
-
Patent number: 9468639Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.Type: GrantFiled: March 6, 2015Date of Patent: October 18, 2016Assignee: Sprout Pharmaceuticals, Inc.Inventors: Franco Borsini, Kenneth Robert Evans
-
Patent number: 9468640Abstract: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.Type: GrantFiled: January 26, 2015Date of Patent: October 18, 2016Assignee: JANSSEN PHARMACEUTICA NVInventors: Marcel Frans Leopold De Bruyn, Gregor James Macdonald, Ludo Edmond Josephine Kennis, Xavier Jean Michel Langlois, Frans Alfons Maria Van den Keybus, Yves Emiel Maria Van Roosbroeck
-
Patent number: 9468641Abstract: Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases.Type: GrantFiled: April 16, 2015Date of Patent: October 18, 2016Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Seung Bum Park, Sanghee Lee, Ja Young Koo, Donghyun Lim, Jongmin Park, Kyoungho Suk, Youngpyo Nam
-
Patent number: 9468642Abstract: The present invention relates to imidazopyrazine compounds of general Formula (I): in which X, R1, R2, R3a, R3b, R4a, R4b, R4C, and R4D are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: March 16, 2011Date of Patent: October 18, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Klar, Marcus Koppitz, Dirk Kosemund, Rolf Bohlmann, Benjamin Bader, Philip Lienau, Gerhard Siemeister, Stefan Prechtl, Duy Nguyen, William Scott
-
Patent number: 9468643Abstract: The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.Type: GrantFiled: May 19, 2014Date of Patent: October 18, 2016Assignee: The Johns Hopkins UniversityInventors: Ivan M. Borrello, Paolo Serafini, Kimberly A. Noonan, Vincenzo Bronte
-
Patent number: 9468644Abstract: Suggested is a non-therapeutic aqueous composition for topical application, comprising (a) at least one solid active agent having at 20° C. a solubility in water (20° dH) of less than 5 g/L; (b) at least one 1,2-alkandiol having 4 to 12 carbon atoms; and (c) at least one aliphatic alcohol having 2 to 4 carbon atoms.Type: GrantFiled: November 5, 2013Date of Patent: October 18, 2016Assignee: Symrise AGInventor: Cecile Kalem
-
Patent number: 9468645Abstract: The invention provides nutritional supplements, in powder, tablet or capsule dosage forms and aqueous formulations, containing one or more of the purine bioactive compounds described including theacrine and theacrine species.Type: GrantFiled: February 23, 2015Date of Patent: October 18, 2016Inventor: Jack Owoc
-
Patent number: 9468646Abstract: The invention is based on the finding that an increased daily dose of Efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of AIDS. The invention thus relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a dose generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml. It further relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a daily dose of at least 1800 mg, in particular between 1800 and 2200 mg. It also relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, in which the daily dose of Efavirenz is optimized after administration of a preliminary daily dose and measure or Efavirenz plasma concentration.Type: GrantFiled: January 23, 2013Date of Patent: October 18, 2016Assignee: ALIENOR FARMAInventors: Pier Vincenzo Piazza, Nadine Houede, Audrey Laroche-Clary
-
Patent number: 9468647Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.Type: GrantFiled: October 27, 2014Date of Patent: October 18, 2016Assignee: MISCON TRADING S.A.Inventor: Mirudhubashini Govindarajan